STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at 4:30 p.m. EST to report fourth quarter and full year 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN. A live audio webcast and archived replay of the call will be available under “Even ...

Cara Therapeutics, Inc. (Cara) Q3 2023 Earnings Call Transcript November 13, 2023 4:30 PM ET Company Participants Matt Murphy - Manager of IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler Annabel Samimy - Stifel Oren Livnat - H.C. Wainwright Operator Good afternoon. My name is Latif and I will be your conference facilitator. I would like to welco ...

CARA THERAPEUTICS, INC. CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (amounts in thousands, excluding share and per share data) (unaudited) Table of Contents 3 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------------------|------------------|-------|----------------------------------|-------------------------|-------|------------------------------------------|------------------------------| | | Common \nShares | Stock \nAmount | | Ad ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Matthew Murphy - Manager, IR Christopher Posner - President, CEO & Director Ryan Maynard - CFO Scott Terrillion - Chief Compliance Officer, General Counsel & Corporate Secretary Conference Call Participants Dennis Ding - Jefferies Annabel Samimy - Stifel, Nicolaus & Company Joseph Stringer - Needham & Company Sumant Kulkarni - Canaccord Genuity David Amsellem - Piper Sandler & Co. Chi Fong - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 COMMISSION FILE NUMBER 001-36279 CARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 75-3175693 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 4 Stamford Plaza 107 Elm Street, 9 th Floor Stamford, Connecticut 06902 (A ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Christopher Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler Chi Fong - Bank of America Securities Sumant Kulkarni - Canaccord Genuity Operator Good afternoon. My name is Lateef, and I will be your conference facilitator. ...

The Company may offer additional securities under its Shelf Registration Statement from time to time in response to market conditions or other circumstances if it believes such a plan of financing is in the best interests of its stockholders. In October 2020, the Company entered into a license agreement with Vifor International, or Vifor Agreement No. 1, under which the Company granted Vifor International an exclusive license solely in the United States to use, distribute, offer for sale, promote, sell and ...

Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler AJ Velasquez-Mao - Jefferies Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Oren Livnat - H.C. Wainwright Sumant K ...

● satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity, as well as satisfactory completion of an FDA inspection of selected clinical sites to determine cGCP compliance; and Preclinical Studies. Preclinical studies include laboratory evalua ...

RUN-IN Double Blind Treatment Period Long-term Safety Extension Treatment Period (Open Label) 7 Days 8 Weeks Up to 52 Weeks Part B and Second Study Oral DFK XX mg BID Oral PBO BID Initiation Part A NP Phase 2/3 (1Q 2023) | --- | |-------------| | | | | | KIND 1b & 2 | | AD Phase 3 | 15 $180M cash position September 30, 2022 • Sufficient resources to continue development of the oral difelikefalin platforms CCARA THERAPEUTICS Prim ary Endpoint KARE STUDY: Phase 2 Data in Atopic Dermatitis (AD) Popula t ion: M ...